{"product_id":"farmacopee-gmp-guida-operativa-usp-ph-eur","title":"Pharmacopoeias in GMP – Operational Guide to USP, Ph. Eur., JP and BP (First Edition + Toolkit)","description":"\u003cdiv style='font-family:-apple-system,BlinkMacSystemFont,system-ui,Roboto,Helvetica,Arial,sans-serif;color:#233047;line-height:1.6'\u003e\u003cdiv style='background:#14243a;background-image:radial-gradient(circle at 80% 10%,#22344e 0%,#14243a 45%,#0d1828 100%);border-radius:14px;padding:34px 30px 30px 30px;color:#ffffff;margin-bottom:26px'\u003e\u003cdiv style='display:inline-block;background:#c9a227;color:#14243a;font-size:12px;font-weight:700;letter-spacing:1.6px;text-transform:uppercase;padding:6px 12px;border-radius:4px;margin-bottom:16px'\u003eFirst edition · September 2026\u003c\/div\u003e\u003ch3 style='margin:0 0 12px 0;font-size:29px;line-height:1.25;color:#ffffff;font-weight:800'\u003eWhich standard actually binds you, which version you are on today, and what you may legitimately do differently\u003c\/h3\u003e\u003cp style='margin:0 0 20px 0;font-size:16px;color:#d7e2f2;max-width:690px'\u003eThis guide does not summarise the pharmacopoeias \u0026mdash; you already subscribe to those. It reconstructs the legal chains that make a compendial text binding, how you establish which version applies today, and the alternative-method regime in the European Union and the United States. 251 pages, 22 chapters across 6 Parts, 184 sources verified as at 14 September 2026, plus 14 editable tools ready to fill in.\u003c\/p\u003e\u003cdiv style='display:flex;flex-wrap:wrap;gap:9px'\u003e\u003cspan style='background:#22344e;color:#d7e2f2;font-size:13px;padding:7px 13px;border-radius:20px'\u003e251 pages · A4 · PDF\u003c\/span\u003e\u003cspan style='background:#22344e;color:#d7e2f2;font-size:13px;padding:7px 13px;border-radius:20px'\u003e22 chapters in 6 Parts\u003c\/span\u003e\u003cspan style='background:#22344e;color:#d7e2f2;font-size:13px;padding:7px 13px;border-radius:20px'\u003e14 editable tools\u003c\/span\u003e\u003cspan style='background:#22344e;color:#d7e2f2;font-size:13px;padding:7px 13px;border-radius:20px'\u003e6 appendices · 184 verified sources\u003c\/span\u003e\u003cspan style='background:#22344e;color:#d7e2f2;font-size:13px;padding:7px 13px;border-radius:20px'\u003eRegulatory cut-off 14\/09\/2026\u003c\/span\u003e\u003c\/div\u003e\u003c\/div\u003e\u003cdiv style='display:flex;flex-wrap:wrap;gap:14px;margin-bottom:30px'\u003e\u003cdiv style='flex:1 1 210px;background:#f6f8fb;border:1px solid #e3e9f2;border-radius:11px;padding:19px'\u003e\u003cdiv style='font-size:12px;font-weight:700;color:#c9a227;letter-spacing:1.2px;text-transform:uppercase;margin-bottom:7px'\u003eThe guide\u003c\/div\u003e\u003cdiv style='font-size:15px;color:#233047'\u003eNot a commentary on monographs, but a guide to the decision. Every chapter follows the same route \u0026mdash; requirement, interpretation, risk, decision, action, evidence, demonstrability \u0026mdash; and closes with the decisions no source makes on your behalf, collected one by one in an appendix.\u003c\/div\u003e\u003c\/div\u003e\u003cdiv style='flex:1 1 210px;background:#f6f8fb;border:1px solid #e3e9f2;border-radius:11px;padding:19px'\u003e\u003cdiv style='font-size:12px;font-weight:700;color:#185abd;letter-spacing:1.2px;text-transform:uppercase;margin-bottom:7px'\u003eThe toolkit\u003c\/div\u003e\u003cdiv style='font-size:15px;color:#233047'\u003e14 editable tools: 8 Excel workbooks with working formulas, drop-down menus, conditional formatting and dashboards, and 6 Word templates already written to 70%, with section-by-section guidance, worked examples, an approval table and a revision history.\u003c\/div\u003e\u003c\/div\u003e\u003cdiv style='flex:1 1 210px;background:#f6f8fb;border:1px solid #e3e9f2;border-radius:11px;padding:19px'\u003e\u003cdiv style='font-size:12px;font-weight:700;color:#c9a227;letter-spacing:1.2px;text-transform:uppercase;margin-bottom:7px'\u003eUpdates included\u003c\/div\u003e\u003cdiv style='font-size:15px;color:#233047'\u003eIncluded for life. When Ph. Eur. Issue 13.1 becomes applicable, when BP 2027 takes legal effect, and when ICH Q3E and Q6(R1) leave draft status, you receive the updated edition at no further cost.\u003c\/div\u003e\u003c\/div\u003e\u003c\/div\u003e\u003cdiv style='background:#0d1828;border-radius:12px;padding:24px 26px;margin-bottom:30px;color:#d7e2f2'\u003e\u003cdiv style='font-size:12px;font-weight:700;color:#c9a227;letter-spacing:1.4px;text-transform:uppercase;margin-bottom:14px'\u003eThe three things this guide says that others do not\u003c\/div\u003e\u003cp style='margin:0 0 14px 0;font-size:15px;line-height:1.65'\u003eThis is not a manual of analytical methods, and it reproduces no monograph. It is the book that answers three questions raised in the laboratory every week, and that almost no text answers in full.\u003c\/p\u003e\u003cp style='margin:0 0 12px 0;font-size:15px;line-height:1.65'\u003e\u003cstrong style='color:#ffffff'\u003eThe Ph. Eur. supplement model no longer exists.\u003c\/strong\u003e Since 2025 there is one edition per year, published in three Issues. The content in force today is that resulting from the Issues up to and including 12.3; 13.1 and 13.2 are already published but become applicable only in 2027. Every company procedure still citing \u0026ldquo;11th ed., Suppl. 11.8\u0026rdquo; points to a versioning model that is gone, and Chapter 6 shows how that cross-reference is rewritten.\u003c\/p\u003e\u003cp style='margin:0 0 12px 0;font-size:15px;line-height:1.65'\u003e\u003cstrong style='color:#ffffff'\u003eThe obligation is conformity to the standard, not execution of the method.\u003c\/strong\u003e The compendial method is the \u003cstrong style='color:#ffffff'\u003ereferee\u003c\/strong\u003e in the event of dispute, not the only procedure permitted. The European Union and the United States reach the same principle through entirely different legal chains \u0026mdash; indirect in Europe, statutory in the United States \u0026mdash; and neither chain transplants into the other. Chapters 2, 3, 9 and 10 walk through them one at a time.\u003c\/p\u003e\u003cp style='margin:0;font-size:15px;line-height:1.65'\u003e\u003cstrong style='color:#ffffff'\u003eNo ICH text resolves the conflict between thresholds and monograph limits.\u003c\/strong\u003e Where a Q3A\/Q3B threshold and a monograph limit diverge, no rule of precedence exists in the verified ICH texts. The guide documents that with the source and, in place of the missing rule, builds the decision method: what you verify first, how the choice is justified, and in what form the rationale still holds years later, when its author has left the company.\u003c\/p\u003e\u003c\/div\u003e\u003ch3 style='font-size:22px;margin:0 0 6px 0;color:#14243a'\u003eThe 14 tools in the toolkit\u003c\/h3\u003e\u003cp style='margin:0 0 18px 0;font-size:15px;color:#5a6b85'\u003eEach tool comes out of the chapter that explains it, and exists in Italian and in English. None carries pre-loaded operational values: where a number would be the answer there is a placeholder, stating who decides, on what basis and where it is recorded \u0026mdash; because a number pre-loaded into a template becomes the user\u0026rsquo;s default.\u003c\/p\u003e\u003cdiv style='display:flex;flex-wrap:wrap;gap:10px;margin-bottom:28px'\u003e\u003cdiv style='flex:1 1 235px;background:#ffffff;border:1px solid #e3e9f2;border-radius:10px;padding:14px'\u003e\u003cspan style='display:inline-block;background:#1d6f42;color:#fff;font-size:10px;font-weight:700;letter-spacing:1px;padding:3px 7px;border-radius:3px;margin-bottom:7px'\u003eEXCEL\u003c\/span\u003e\u003cdiv style='font-weight:700;font-size:14.5px;color:#14243a;margin-bottom:4px'\u003eT-01 · Compendial version surveillance register\u003c\/div\u003e\u003cdiv style='font-size:13.5px;color:#5a6b85'\u003eText by text, which version applies today, which is published but not yet applicable, and which company documents depend on each one.\u003c\/div\u003e\u003c\/div\u003e\u003cdiv style='flex:1 1 235px;background:#ffffff;border:1px solid #e3e9f2;border-radius:10px;padding:14px'\u003e\u003cspan style='display:inline-block;background:#1d6f42;color:#fff;font-size:10px;font-weight:700;letter-spacing:1px;padding:3px 7px;border-radius:3px;margin-bottom:7px'\u003eEXCEL\u003c\/span\u003e\u003cdiv style='font-weight:700;font-size:14.5px;color:#14243a;margin-bottom:4px'\u003eT-02 · Multi-region divergence matrix\u003c\/div\u003e\u003cdiv style='font-size:13.5px;color:#5a6b85'\u003eMakes visible what actually diverges between the pharmacopoeias of the markets you serve, parameter by parameter and with two dates on every row.\u003c\/div\u003e\u003c\/div\u003e\u003cdiv style='flex:1 1 235px;background:#ffffff;border:1px solid #e3e9f2;border-radius:10px;padding:14px'\u003e\u003cspan style='display:inline-block;background:#1d6f42;color:#fff;font-size:10px;font-weight:700;letter-spacing:1px;padding:3px 7px;border-radius:3px;margin-bottom:7px'\u003eEXCEL\u003c\/span\u003e\u003cdiv style='font-weight:700;font-size:14.5px;color:#14243a;margin-bottom:4px'\u003eT-03 · Reference standards register\u003c\/div\u003e\u003cdiv style='font-size:13.5px;color:#5a6b85'\u003eAnswers the question that always comes up here: does this lot still hold official status, and when was that last checked.\u003c\/div\u003e\u003c\/div\u003e\u003cdiv style='flex:1 1 235px;background:#ffffff;border:1px solid #e3e9f2;border-radius:10px;padding:14px'\u003e\u003cspan style='display:inline-block;background:#1d6f42;color:#fff;font-size:10px;font-weight:700;letter-spacing:1px;padding:3px 7px;border-radius:3px;margin-bottom:7px'\u003eEXCEL\u003c\/span\u003e\u003cdiv style='font-weight:700;font-size:14.5px;color:#14243a;margin-bottom:4px'\u003eT-04 · Alternative method decision tree, EU \/ US\u003c\/div\u003e\u003cdiv style='font-size:13.5px;color:#5a6b85'\u003eEstablishes which regime your method sits in, with a separate outcome per jurisdiction: for a multi-market product the path is walked twice.\u003c\/div\u003e\u003c\/div\u003e\u003cdiv style='flex:1 1 235px;background:#ffffff;border:1px solid #e3e9f2;border-radius:10px;padding:14px'\u003e\u003cspan style='display:inline-block;background:#1d6f42;color:#fff;font-size:10px;font-weight:700;letter-spacing:1px;padding:3px 7px;border-radius:3px;margin-bottom:7px'\u003eEXCEL\u003c\/span\u003e\u003cdiv style='font-weight:700;font-size:14.5px;color:#14243a;margin-bottom:4px'\u003eT-05 · Adjustment or modification? Chromatographic adjustments\u003c\/div\u003e\u003cdiv style='font-size:13.5px;color:#5a6b85'\u003eParameter by parameter, whether the deviation is an adjustment the general chapter permits or a modification of the method, always calculated from the compendial value.\u003c\/div\u003e\u003c\/div\u003e\u003cdiv style='flex:1 1 235px;background:#ffffff;border:1px solid #e3e9f2;border-radius:10px;padding:14px'\u003e\u003cspan style='display:inline-block;background:#1d6f42;color:#fff;font-size:10px;font-weight:700;letter-spacing:1px;padding:3px 7px;border-radius:3px;margin-bottom:7px'\u003eEXCEL\u003c\/span\u003e\u003cdiv style='font-weight:700;font-size:14.5px;color:#14243a;margin-bottom:4px'\u003eT-06 · Compendial method verification plan\u003c\/div\u003e\u003cdiv style='font-size:13.5px;color:#5a6b85'\u003eGoverns the portfolio: how many compendial methods you run, which are covered, and why the uncovered ones are not.\u003c\/div\u003e\u003c\/div\u003e\u003cdiv style='flex:1 1 235px;background:#ffffff;border:1px solid #e3e9f2;border-radius:10px;padding:14px'\u003e\u003cspan style='display:inline-block;background:#1d6f42;color:#fff;font-size:10px;font-weight:700;letter-spacing:1px;padding:3px 7px;border-radius:3px;margin-bottom:7px'\u003eEXCEL\u003c\/span\u003e\u003cdiv style='font-weight:700;font-size:14.5px;color:#14243a;margin-bottom:4px'\u003eT-07 · Impurity assessment: ICH threshold against monograph limit\u003c\/div\u003e\u003cdiv style='font-size:13.5px;color:#5a6b85'\u003eDocuments the divergence at the moment it is detected and preserves the rationale in a form that still holds years later.\u003c\/div\u003e\u003c\/div\u003e\u003cdiv style='flex:1 1 235px;background:#ffffff;border:1px solid #e3e9f2;border-radius:10px;padding:14px'\u003e\u003cspan style='display:inline-block;background:#1d6f42;color:#fff;font-size:10px;font-weight:700;letter-spacing:1px;padding:3px 7px;border-radius:3px;margin-bottom:7px'\u003eEXCEL\u003c\/span\u003e\u003cdiv style='font-weight:700;font-size:14.5px;color:#14243a;margin-bottom:4px'\u003eT-08 · Compendial audit-readiness dashboard\u003c\/div\u003e\u003cdiv style='font-size:13.5px;color:#5a6b85'\u003eShows, before an inspection does, how much of the questioning your system actually covers and where the gaps sit.\u003c\/div\u003e\u003c\/div\u003e\u003cdiv style='flex:1 1 235px;background:#ffffff;border:1px solid #e3e9f2;border-radius:10px;padding:14px'\u003e\u003cspan style='display:inline-block;background:#185abd;color:#fff;font-size:10px;font-weight:700;letter-spacing:1px;padding:3px 7px;border-radius:3px;margin-bottom:7px'\u003eWORD\u003c\/span\u003e\u003cdiv style='font-weight:700;font-size:14.5px;color:#14243a;margin-bottom:4px'\u003eT-09 · SOP \u0026mdash; Pharmacopoeial surveillance and revision management\u003c\/div\u003e\u003cdiv style='font-size:13.5px;color:#5a6b85'\u003eGives an owner, a workflow and a record to an activity spanning laboratory, quality and regulatory, and which, when it belongs to everyone, belongs to no one.\u003c\/div\u003e\u003c\/div\u003e\u003cdiv style='flex:1 1 235px;background:#ffffff;border:1px solid #e3e9f2;border-radius:10px;padding:14px'\u003e\u003cspan style='display:inline-block;background:#185abd;color:#fff;font-size:10px;font-weight:700;letter-spacing:1px;padding:3px 7px;border-radius:3px;margin-bottom:7px'\u003eWORD\u003c\/span\u003e\u003cdiv style='font-weight:700;font-size:14.5px;color:#14243a;margin-bottom:4px'\u003eT-10 · SOP \u0026mdash; Qualification and management of reference standards\u003c\/div\u003e\u003cdiv style='font-size:13.5px;color:#5a6b85'\u003eTwo separate status-verification processes, one for the USP system and one for the Ph. Eur. system, because the mechanisms do not coincide.\u003c\/div\u003e\u003c\/div\u003e\u003cdiv style='flex:1 1 235px;background:#ffffff;border:1px solid #e3e9f2;border-radius:10px;padding:14px'\u003e\u003cspan style='display:inline-block;background:#185abd;color:#fff;font-size:10px;font-weight:700;letter-spacing:1px;padding:3px 7px;border-radius:3px;margin-bottom:7px'\u003eWORD\u003c\/span\u003e\u003cdiv style='font-weight:700;font-size:14.5px;color:#14243a;margin-bottom:4px'\u003eT-11 · Compendial method verification protocol\u003c\/div\u003e\u003cdiv style='font-size:13.5px;color:#5a6b85'\u003eSelected performance characteristics with the rationale for the selection, and criteria fixed in advance: a protocol that leaves them open is not a protocol.\u003c\/div\u003e\u003c\/div\u003e\u003cdiv style='flex:1 1 235px;background:#ffffff;border:1px solid #e3e9f2;border-radius:10px;padding:14px'\u003e\u003cspan style='display:inline-block;background:#185abd;color:#fff;font-size:10px;font-weight:700;letter-spacing:1px;padding:3px 7px;border-radius:3px;margin-bottom:7px'\u003eWORD\u003c\/span\u003e\u003cdiv style='font-weight:700;font-size:14.5px;color:#14243a;margin-bottom:4px'\u003eT-12 · Alternative method justification rationale\u003c\/div\u003e\u003cdiv style='font-size:13.5px;color:#5a6b85'\u003eThe document missing from inherited method files, in a European and a US version: two markets need two rationales, not one translated.\u003c\/div\u003e\u003c\/div\u003e\u003cdiv style='flex:1 1 235px;background:#ffffff;border:1px solid #e3e9f2;border-radius:10px;padding:14px'\u003e\u003cspan style='display:inline-block;background:#185abd;color:#fff;font-size:10px;font-weight:700;letter-spacing:1px;padding:3px 7px;border-radius:3px;margin-bottom:7px'\u003eWORD\u003c\/span\u003e\u003cdiv style='font-weight:700;font-size:14.5px;color:#14243a;margin-bottom:4px'\u003eT-13 · Monograph revision impact assessment report\u003c\/div\u003e\u003cdiv style='font-size:13.5px;color:#5a6b85'\u003eThe downstream chain of every revision: what it touches, what was decided, by when, and with which amended documents and their effective dates.\u003c\/div\u003e\u003c\/div\u003e\u003cdiv style='flex:1 1 235px;background:#ffffff;border:1px solid #e3e9f2;border-radius:10px;padding:14px'\u003e\u003cspan style='display:inline-block;background:#185abd;color:#fff;font-size:10px;font-weight:700;letter-spacing:1px;padding:3px 7px;border-radius:3px;margin-bottom:7px'\u003eWORD\u003c\/span\u003e\u003cdiv style='font-weight:700;font-size:14.5px;color:#14243a;margin-bottom:4px'\u003eT-14 · Inspector response pack on compendial matters\u003c\/div\u003e\u003cdiv style='font-size:13.5px;color:#5a6b85'\u003eWho answers for each macro-area, with which documents and where they live. It holds references, not copies.\u003c\/div\u003e\u003c\/div\u003e\u003c\/div\u003e\u003ch3 style='font-size:22px;margin:0 0 14px 0;color:#14243a'\u003eYou use it from tomorrow morning\u003c\/h3\u003e\u003ctable style='width:100%;border-collapse:collapse;font-size:14.5px;margin-bottom:28px'\u003e\u003ctr style='background:#14243a;color:#fff'\u003e\u003cth style='text-align:left;padding:11px 13px'\u003eThe situation\u003c\/th\u003e\u003cth style='text-align:left;padding:11px 13px'\u003eWhat you use\u003c\/th\u003e\u003c\/tr\u003e\u003ctr style='background:#f6f8fb'\u003e\u003ctd style='padding:11px 13px;border-bottom:1px solid #e3e9f2'\u003e\u0026ldquo;Which version of the Ph. Eur. are we on, exactly?\u0026rdquo;\u003c\/td\u003e\u003ctd style='padding:11px 13px;border-bottom:1px solid #e3e9f2'\u003eChapter 6 + T-01: the Issue model, the end of supplements, and the register that watches text by text\u003c\/td\u003e\u003c\/tr\u003e\u003ctr\u003e\u003ctd style='padding:11px 13px;border-bottom:1px solid #e3e9f2'\u003eOne of your procedures still cites \u0026ldquo;Suppl. 11.8\u0026rdquo;\u003c\/td\u003e\u003ctd style='padding:11px 13px;border-bottom:1px solid #e3e9f2'\u003eChapters 5 and 6 + T-09: how the cross-reference is rewritten, and the SOP that stops it recurring\u003c\/td\u003e\u003c\/tr\u003e\u003ctr style='background:#f6f8fb'\u003e\u003ctd style='padding:11px 13px;border-bottom:1px solid #e3e9f2'\u003eYou want to run a method other than the monograph one, in the EU\u003c\/td\u003e\u003ctd style='padding:11px 13px;border-bottom:1px solid #e3e9f2'\u003eChapter 9 + T-04 and T-12: the three cumulative conditions, who the competent authority actually is, and the rationale that records them\u003c\/td\u003e\u003c\/tr\u003e\u003ctr\u003e\u003ctd style='padding:11px 13px;border-bottom:1px solid #e3e9f2'\u003eThe same method, but for the US market\u003c\/td\u003e\u003ctd style='padding:11px 13px;border-bottom:1px solid #e3e9f2'\u003eChapter 10 + T-04 and T-12: commitment in the filing, sole appropriateness of the official method, referee test and the 21 CFR duties that remain\u003c\/td\u003e\u003c\/tr\u003e\u003ctr style='background:#f6f8fb'\u003e\u003ctd style='padding:11px 13px;border-bottom:1px solid #e3e9f2'\u003eThe ICH threshold and the monograph limit do not agree\u003c\/td\u003e\u003ctd style='padding:11px 13px;border-bottom:1px solid #e3e9f2'\u003eChapters 15 and 19 + T-07: the conflict no text resolves, and how the decision is justified and preserved\u003c\/td\u003e\u003c\/tr\u003e\u003ctr\u003e\u003ctd style='padding:11px 13px;border-bottom:1px solid #e3e9f2'\u003eYou export to several regions on one specification\u003c\/td\u003e\u003ctd style='padding:11px 13px;border-bottom:1px solid #e3e9f2'\u003eChapter 16 + T-02: the divergence map is built before the strategy, not after it\u003c\/td\u003e\u003c\/tr\u003e\u003ctr style='background:#f6f8fb'\u003e\u003ctd style='padding:11px 13px;border-bottom:1px solid #e3e9f2'\u003eThe inspector asks whether that standard lot is still official\u003c\/td\u003e\u003ctd style='padding:11px 13px;border-bottom:1px solid #e3e9f2'\u003eChapter 17 + T-03 and T-10: lot status, date of the check, operator, and traceability back to the primary\u003c\/td\u003e\u003c\/tr\u003e\u003ctr\u003e\u003ctd style='padding:11px 13px;border-bottom:1px solid #e3e9f2'\u003eYou adjusted the chromatography and are unsure you could\u003c\/td\u003e\u003ctd style='padding:11px 13px;border-bottom:1px solid #e3e9f2'\u003eChapter 12 + T-05: always calculate from the value written in the pharmacopoeial procedure, then assess the combined effect\u003c\/td\u003e\u003c\/tr\u003e\u003ctr style='background:#f6f8fb'\u003e\u003ctd style='padding:11px 13px'\u003eInspection in two weeks\u003c\/td\u003e\u003ctd style='padding:11px 13px'\u003eChapters 21 and 22 + T-08 and T-14: the seven macro-areas, the open gaps, and who answers for each\u003c\/td\u003e\u003c\/tr\u003e\u003c\/table\u003e\u003cdiv style='background:#fdf6e3;border-left:4px solid #c9a227;border-radius:0 9px 9px 0;padding:19px 21px;margin-bottom:28px'\u003e\u003cdiv style='font-weight:700;color:#7a5c00;font-size:15px;margin-bottom:8px'\u003eRegulatory rigour, declared line by line\u003c\/div\u003e\u003cdiv style='font-size:14.5px;color:#4a4530'\u003eEvery regulatory statement carries exactly one label out of \u003cstrong\u003eeight\u003c\/strong\u003e: \u003cstrong\u003e[REQUIREMENT]\u003c\/strong\u003e for a binding legal obligation, \u003cstrong\u003e[PHARMACOPOEIA]\u003c\/strong\u003e for a pharmacopoeial provision \u0026mdash; which is not in itself a legal obligation and becomes one only through the legal chain of the jurisdiction \u0026mdash; \u003cstrong\u003e[GUIDANCE]\u003c\/strong\u003e for the expectation of a non-binding guidance, \u003cstrong\u003e[GOOD PRACTICE]\u003c\/strong\u003e for settled industry practice with no text imposing it, \u003cstrong\u003e[QRM]\u003c\/strong\u003e for a decision the organisation must take and justify, \u003cstrong\u003e[GUIDEGXP]\u003c\/strong\u003e for an author\u0026rsquo;s interpretation declared as such, \u003cstrong\u003e[DRAFT]\u003c\/strong\u003e for a public text with no regulatory force, and \u003cstrong\u003e[NOT YET APPLICABLE]\u003c\/strong\u003e for an adopted text with a future effective date, always carrying that date. The distinction between the first two is the reason this volume exists.\u003cbr\u003e\u003cbr\u003eThe status of every source is verified as at \u003cstrong\u003e14 September 2026\u003c\/strong\u003e, and every text cited carries two separate dates: publication and application. The \u003cstrong\u003e184 sources\u003c\/strong\u003e are listed in an appendix with document, version, date, URL and verification status; where a source sits behind a subscription or returned a block on the date of consultation, the text says so and points to where the figure is read, instead of quoting it from memory.\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eNo operational value is pre-loaded.\u003c\/strong\u003e Surveillance frequencies, validity periods, internal thresholds and acceptance criteria cannot be derived from a pharmacopoeia: in the guide and in the templates they appear as placeholders, with who decides, on what basis and where it is recorded. \u003cstrong\u003eNo table of compendial limits is reproduced\u003c\/strong\u003e, out of respect for the copyright of USP, EDQM, PMDA and the British Pharmacopoeia Commission \u0026mdash; and because the number ages while the structure of the decision does not. The guide teaches where to read it and how to demonstrate that you did. Company, site and case-study data are openly fictional, and no real inspection finding is reported, quoted or paraphrased.\u003c\/div\u003e\u003c\/div\u003e\u003ch3 style='font-size:22px;margin:0 0 12px 0;color:#14243a'\u003eWhat is inside\u003c\/h3\u003e\u003cdiv style='font-size:15px;color:#233047;margin-bottom:28px'\u003e\u003cp style='margin:0 0 9px 0'\u003e\u003cstrong style='color:#14243a'\u003ePart I \u0026mdash; Who binds you, and to what.\u003c\/strong\u003e The pharmacopoeias that matter: who writes them, what they contain and why they are not interchangeable. The European chain, from Annex I of Dir. 2001\/83\/EC to the method approved in the marketing authorisation. The US chain: FD\u0026amp;C Act §501(b), adulteration and the referee. Japan, the United Kingdom and Ph. Int., the other three chains. (Chapters 1\u0026ndash;4)\u003c\/p\u003e\u003cp style='margin:0 0 9px 0'\u003e\u003cstrong style='color:#14243a'\u003ePart II \u0026mdash; Which version is in force today.\u003c\/strong\u003e Standard is not method, and version is not edition. Ph. Eur.: the Issue model and the end of supplements. USP\u0026ndash;NF: six issues a year and the Accelerated Revisions that overtake them, with the CURRENTLY OFFICIAL marker as the only usable reference. Version surveillance: building the system and demonstrating it. (Chapters 5\u0026ndash;8)\u003c\/p\u003e\u003cp style='margin:0 0 9px 0'\u003e\u003cstrong style='color:#14243a'\u003ePart III \u0026mdash; The alternative method.\u003c\/strong\u003e The three cumulative European conditions, and who the competent authority really is. The US rule: CPG 420.400 and the referee test. Verification, validation and transfer: three different operations that get confused. Permitted adjustments in chromatography: where adjustment ends and modification begins. (Chapters 9\u0026ndash;12)\u003c\/p\u003e\u003cp style='margin:0 0 9px 0'\u003e\u003cstrong style='color:#14243a'\u003ePart IV \u0026mdash; When pharmacopoeias diverge.\u003c\/strong\u003e \u0026ldquo;Harmonised\u0026rdquo; does not mean \u0026ldquo;identical\u0026rdquo;: the four-member PDG. ICH Q4B and interchangeability, and what it actually permits. ICH against the monograph: the conflict no text resolves. Governing divergence across regions, with the three strategies and their costs. (Chapters 13\u0026ndash;16)\u003c\/p\u003e\u003cp style='margin:0 0 9px 0'\u003e\u003cstrong style='color:#14243a'\u003ePart V \u0026mdash; The operational areas.\u003c\/strong\u003e Reference standards: current lots, secondary standards, and the traceability the inspector asks for. Dissolution and compendial methods, where the method is the product. Organic and elemental impurities and residual solvents. The shared perimeter: sterility, endotoxins, particulate matter. (Chapters 17\u0026ndash;20)\u003c\/p\u003e\u003cp style='margin:0 0 9px 0'\u003e\u003cstrong style='color:#14243a'\u003ePart VI \u0026mdash; Demonstrating it in inspection.\u003c\/strong\u003e What the inspector looks at on compendial matters, across the seven macro-areas and in the form the questions are actually asked. The defensibility file, with five cases worked from start to close and linked to each tool. (Chapters 21\u0026ndash;22)\u003c\/p\u003e\u003cp style='margin:0'\u003ePlus six appendices: the register of 184 verified sources with their verification status, the operational IT\/EN glossary, the full register of decisions to be taken with who decides and where it is recorded, the datasheets for the fourteen tools, the comparative chapter map across pharmacopoeias, and the 2026\u0026ndash;2028 regulatory calendar.\u003c\/p\u003e\u003c\/div\u003e\u003cdiv style='background:#f6f8fb;border:1px solid #e3e9f2;border-radius:12px;padding:22px 24px;margin-bottom:28px'\u003e\u003ch3 style='font-size:22px;margin:0 0 8px 0;color:#14243a'\u003eRead the preview before you buy\u003c\/h3\u003e\u003cp style='margin:0 0 16px 0;font-size:15px;color:#5a6b85;max-width:690px'\u003eThe free preview contains the Regulatory Status Box as at 14 September 2026, the legend of the eight labels, the full table of contents, the opening chapter and the overview of the fourteen tools. The preview exists in Italian and in English, as does the guide.\u003c\/p\u003e\u003cdiv style='display:flex;flex-wrap:wrap;gap:10px'\u003e\u003ca href='https:\/\/cdn.shopify.com\/s\/files\/1\/0955\/3320\/3786\/files\/GuideGxP_Farmacopee_GMP_1ed_PREVIEW_ITA.pdf?v=1789490238' style='display:inline-block;background:#14243a;color:#ffffff;font-weight:700;font-size:15px;text-decoration:none;padding:12px 22px;border-radius:6px'\u003eFree preview \u0026mdash; Italian (PDF)\u003c\/a\u003e\u003ca href='https:\/\/cdn.shopify.com\/s\/files\/1\/0955\/3320\/3786\/files\/GuideGxP_Pharmacopoeias_GMP_1ed_PREVIEW_ENG.pdf?v=1789490238' style='display:inline-block;background:#ffffff;color:#14243a;border:1.5px solid #14243a;font-weight:700;font-size:15px;text-decoration:none;padding:11px 21px;border-radius:6px'\u003eFree preview \u0026mdash; English (PDF)\u003c\/a\u003e\u003c\/div\u003e\u003c\/div\u003e\u003ch3 style='font-size:22px;margin:0 0 14px 0;color:#14243a'\u003eSpecifications\u003c\/h3\u003e\u003ctable style='width:100%;border-collapse:collapse;font-size:14.5px;margin-bottom:24px'\u003e\u003ctr style='background:#f6f8fb'\u003e\u003ctd style='padding:10px 13px;width:34%;font-weight:600;color:#14243a;border-bottom:1px solid #e3e9f2'\u003eFormat\u003c\/td\u003e\u003ctd style='padding:10px 13px;border-bottom:1px solid #e3e9f2'\u003ePDF A4, 251 pages (EN edition) · 273 pages (IT edition)\u003c\/td\u003e\u003c\/tr\u003e\u003ctr\u003e\u003ctd style='padding:10px 13px;width:34%;font-weight:600;color:#14243a;border-bottom:1px solid #e3e9f2'\u003eStructure\u003c\/td\u003e\u003ctd style='padding:10px 13px;border-bottom:1px solid #e3e9f2'\u003e22 chapters in 6 Parts + 6 appendices\u003c\/td\u003e\u003c\/tr\u003e\u003ctr style='background:#f6f8fb'\u003e\u003ctd style='padding:10px 13px;width:34%;font-weight:600;color:#14243a;border-bottom:1px solid #e3e9f2'\u003eToolkit\u003c\/td\u003e\u003ctd style='padding:10px 13px;border-bottom:1px solid #e3e9f2'\u003e14 editable tools (8 Excel, 6 Word), in Italian and in English\u003c\/td\u003e\u003c\/tr\u003e\u003ctr\u003e\u003ctd style='padding:10px 13px;width:34%;font-weight:600;color:#14243a;border-bottom:1px solid #e3e9f2'\u003eSources\u003c\/td\u003e\u003ctd style='padding:10px 13px;border-bottom:1px solid #e3e9f2'\u003e184 verified sources, each with document, version, date, URL and verification status\u003c\/td\u003e\u003c\/tr\u003e\u003ctr style='background:#f6f8fb'\u003e\u003ctd style='padding:10px 13px;width:34%;font-weight:600;color:#14243a;border-bottom:1px solid #e3e9f2'\u003ePharmacopoeias covered\u003c\/td\u003e\u003ctd style='padding:10px 13px;border-bottom:1px solid #e3e9f2'\u003eUSP\u0026ndash;NF, Ph. Eur., JP, BP and Ph. Int., plus the PDG, ICH Q4B and the EU and US GMP framework\u003c\/td\u003e\u003c\/tr\u003e\u003ctr\u003e\u003ctd style='padding:10px 13px;width:34%;font-weight:600;color:#14243a;border-bottom:1px solid #e3e9f2'\u003eLanguages\u003c\/td\u003e\u003ctd style='padding:10px 13px;border-bottom:1px solid #e3e9f2'\u003eGuide, preview and toolkit exist in Italian and in English. Select the ITA or ENG variant before purchasing\u003c\/td\u003e\u003c\/tr\u003e\u003ctr style='background:#f6f8fb'\u003e\u003ctd style='padding:10px 13px;width:34%;font-weight:600;color:#14243a;border-bottom:1px solid #e3e9f2'\u003eEdition\u003c\/td\u003e\u003ctd style='padding:10px 13px;border-bottom:1px solid #e3e9f2'\u003eFirst edition, September 2026 · regulatory cut-off 14\/09\/2026, verified against official sources\u003c\/td\u003e\u003c\/tr\u003e\u003ctr\u003e\u003ctd style='padding:10px 13px;width:34%;font-weight:600;color:#14243a;border-bottom:1px solid #e3e9f2'\u003eDelivery\u003c\/td\u003e\u003ctd style='padding:10px 13px;border-bottom:1px solid #e3e9f2'\u003eImmediate download after purchase\u003c\/td\u003e\u003c\/tr\u003e\u003ctr style='background:#f6f8fb'\u003e\u003ctd style='padding:10px 13px;width:34%;font-weight:600;color:#14243a'\u003eLicence\u003c\/td\u003e\u003ctd style='padding:10px 13px'\u003eIndividual use, internal to the purchasing company\u003c\/td\u003e\u003c\/tr\u003e\u003c\/table\u003e\u003cdiv style='background:#f6f8fb;border:1px solid #e3e9f2;border-radius:11px;padding:18px 21px;margin-bottom:24px;font-size:14.5px;color:#233047'\u003e\u003cstrong style='color:#14243a'\u003eWho it is for.\u003c\/strong\u003e QC Managers, QA Managers, senior QC laboratory analysts, Qualified Persons, Regulatory Affairs, method owners, auditors and consultants \u0026mdash; and in particular anyone exporting to several regions, or about to. It is written for professionals: it does not explain what a pharmacopoeia is, it explains which one binds you, in which version, and how you demonstrate it months later.\u003c\/div\u003e\u003cdiv style='background:#14243a;background-image:linear-gradient(135deg,#22344e 0%,#0d1828 100%);border-radius:12px;padding:24px 26px;color:#fff;margin-bottom:20px'\u003e\u003cdiv style='font-size:18px;font-weight:700;margin-bottom:8px;color:#ffffff'\u003eDo you have an open compendial issue on a product or a market?\u003c\/div\u003e\u003cdiv style='font-size:15px;color:#d7e2f2;margin-bottom:16px;max-width:640px'\u003eDescribe the need and request support from a selected specialist.\u003c\/div\u003e\u003ca href='https:\/\/www.guidegxp.com\/pages\/expert-support?area=qualification-lifecycle\u0026amp;source=product-farmacopee-gmp-guide\u0026amp;cta=product-page' style='display:inline-block;background:#c9a227;color:#14243a;font-weight:700;font-size:15px;text-decoration:none;padding:12px 22px;border-radius:6px'\u003eRequest specialist support\u003c\/a\u003e\u003c\/div\u003e\u003cp style='font-size:12.5px;color:#8a90a0;margin:0'\u003eGuideGxP guides do not replace official regulations or compendial texts (USP\u0026ndash;NF, Ph. Eur., JP, BP, Ph. Int., EMA, EU GMP, ICH, PIC\/S, WHO, FDA, CFR): they are operational support tools, and the user remains responsible for applying the rules in force in their own corporate context and for verifying data against official sources on the date of use. Operational parameters have no universal value and must be defined and justified through risk management. GuideGxP is an independent publisher, not affiliated with any regulatory authority, pharmacopoeia or standards body. Digital product: no physical shipment.\u003c\/p\u003e\u003c\/div\u003e","brand":"GuideGxP","offers":[{"title":"ITA - Italiano","offer_id":63536898933066,"sku":null,"price":179.0,"currency_code":"EUR","in_stock":true},{"title":"ENG - English","offer_id":63536912433482,"sku":null,"price":179.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0955\/3320\/3786\/files\/00_cover_3D.png?v=1789464057","url":"https:\/\/www.guidegxp.com\/products\/pharmacopoeias-gmp-operational-guide-usp-ph-eur","provider":"GuideGxP","version":"1.0","type":"link"}